MCID: ANP001
MIFTS: 59

Anaplastic Large Cell Lymphoma

Categories: Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 38 12 53 59 55 15
Anaplastic Large-Cell Lymphoma 37 29
Alcl 53 59
Cd30 Positive Anaplastic Large Cell Lymphoma 59
Ki-1 Positive Anaplastic Large Cell Lymphoma 59
Ki-1+ Anaplastic Large Cell Lymphoma 73
Primary Systemic Alcl 59
Sacl 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
Orphanet 59 ORPHA98841
UMLS via Orphanet 74 C0206180
MESH via Orphanet 45 D017728
ICD10 via Orphanet 34 C84.6 C84.7
KEGG 37 H01601
UMLS 73 C0206180

Summaries for Anaplastic Large Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as anaplastic large-cell lymphoma, is related to primary cutaneous anaplastic large cell lymphoma and alk-positive anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is LINC01013 (Long Intergenic Non-Protein Coding RNA 1013
Our microarray analyses revealed that LINC01013, a novel non-coding RNA gene, was highly expressed in clinical specimens of ALCL and was significantly upregulated in invasive ALCL cell lines.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Adcetris and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Wikipedia : 76 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous anaplastic large cell lymphoma 33.5 ALK GZMB MUC1 NPM1 PTPRC
2 alk-positive anaplastic large cell lymphoma 33.2 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 lymphoma 31.9 ALK NPM1 PAX5 TNFRSF8
4 lymphomatoid papulosis 31.6 ALK GZMB NPM1
5 peripheral t-cell lymphoma 31.0 ALK GZMB TNFRSF8
6 inflammatory myofibroblastic tumor 31.0 ALK NPM1 RNF213
7 histiocytosis 30.7 CSF1R PTPRC TNFRSF8
8 malignant fibroxanthoma 30.3 ALK MUC1 PTPRC
9 mycosis fungoides 30.2 CLU GZMB STAT3 TNFRSF8
10 composite lymphoma 30.1 GZMB PAX5
11 reticulosarcoma 29.9 ALK CLU GZMB MUC1 NPM1 PAX5
12 lymphoma, hodgkin, classic 29.7 ALK GZMB PAX5 PTPRC TNFSF8
13 combined immunodeficiency, x-linked 29.6 IL9 JAK3 PTPRC
14 leukemia, acute myeloid 29.3 CSF1R MCL1 NPM1 PTPRC STAT3
15 severe combined immunodeficiency 29.1 IL9 JAK3 PTPRC
16 leukemia, chronic lymphocytic 28.4 MCL1 PAX5 STAT3 TNFRSF8 TNFSF8
17 alk-negative anaplastic large cell lymphoma 12.6
18 anaplastic small cell lymphoma 11.6
19 eccrine porocarcinoma 10.6 MUC1 STAT3
20 colon lymphoma 10.5 ALK PTPRC TNFRSF8
21 tenosynovial giant cell tumor 10.5 CLU CSF1R
22 conventional fibrosarcoma 10.4 PTPRC TNFRSF8
23 reticulum cell sarcoma 10.4 MUC1 PTPRC TNFRSF8
24 malignant leydig cell tumor 10.4 PAX5 TNFRSF8
25 nodular lymphocyte predominant hodgkin lymphoma 10.4 PAX5 PTPRC
26 autoimmune lymphoproliferative syndrome, type v 10.3
27 histiocytic and dendritic cell cancer 10.3 CLU PTPRC
28 testicular infarct 10.3 PTPRC TNFRSF8
29 adult lymphoma 10.3 ALK TNFRSF8
30 b-cell lymphomas 10.3
31 leukemia 10.3
32 lymphatic system cancer 10.3 ALK NPM1 PTPRC TNFRSF8
33 myeloid sarcoma 10.2 NPM1 PAX5 PTPRC
34 hemophagocytic lymphohistiocytosis 10.2
35 diffuse large b-cell lymphoma 10.2
36 sarcoma 10.2
37 jak3-deficient severe combined immunodeficiency 10.1 IL9 JAK3
38 adult t-cell leukemia 10.1
39 dermatitis 10.1
40 cerebritis 10.1
41 t-cell leukemia 10.1
42 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
43 acute promyelocytic leukemia 10.1 CSF1R NPM1 PTPRC STAT3
44 lung lymphoma 10.0 ALK GZMB PAX5 TNFRSF8
45 panniculitis 10.0
46 squamous cell carcinoma 10.0
47 myeloid leukemia 10.0
48 soft tissue sarcoma 10.0
49 anaplastic ependymoma 10.0 MUC1 RNF213
50 hodgkin's lymphoma, lymphocytic depletion 10.0 ALK PAX5 PTPRC TNFRSF8

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 JAK3 MCL1 PTPRC RNF213 ALK STAT3
2 hematopoietic system MP:0005397 9.85 JAK3 JUNB MCL1 NPM1 PAX5 PTPRC
3 immune system MP:0005387 9.73 JAK3 JUNB MCL1 NPM1 PAX5 PTPRC
4 neoplasm MP:0002006 9.1 JUNB NPM1 PAX5 PTPRC ALK STAT3

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
6
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
10
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
12
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
16
Vindesine Approved, Investigational Phase 4,Not Applicable 59917-39-4, 53643-48-4 40839
17
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 51-75-2 4033
18
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
22
Pirarubicin Investigational Phase 4 72496-41-4
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
34 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 0
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
4 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
5 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
6 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
7 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
11 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
12 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
15 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
16 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
19 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
21 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
22 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
27 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
30 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
31 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
32 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
33 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
36 CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Unknown status NCT02274584 Phase 1, Phase 2
37 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
38 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
39 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
40 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
45 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed NCT00117988 Phase 2 tanespimycin
46 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed NCT01492088 Phase 1, Phase 2 Brentuximab vedotin
47 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Completed NCT00099255 Phase 2 SGN-30
48 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed NCT00866047 Phase 2 brentuximab vedotin
49 Combination Chemotherapy in Treating Children With Lymphoma Completed NCT00002590 Phase 2 cyclophosphamide;cytarabine;daunorubicin hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
50 Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00278382 Phase 2 sorafenib tosylate

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large-Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

41
T Cells, Breast, Bone, Bone Marrow, B Cells, Liver, Skin

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 1076)
# Title Authors Year
1
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
2
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
3
Improvement of cutaneous anaplastic large cell lymphoma by brentuximab vedotin monotherapy. ( 29391331 )
2018
4
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 29801080 )
2018
5
CD30-positive primary cutaneous anaplastic large cell lymphoma with coexistent pseudocarcinomatous hyperplasia. ( 29473196 )
2018
6
Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma. ( 29434148 )
2018
7
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. ( 29512859 )
2018
8
Response to "Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis". ( 29365059 )
2018
9
Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. ( 29445921 )
2018
10
Primary cutaneous anaplastic large-cell lymphoma: A case report. ( 29369180 )
2018
11
Characterization and diagnostic application of genomic <i>NPM-ALK</i> fusion sequences in anaplastic large-cell lymphoma. ( 29899875 )
2018
12
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/I^-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. ( 29609590 )
2018
13
Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. ( 29921615 )
2018
14
Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma. ( 29719098 )
2018
15
Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis. ( 29365043 )
2018
16
Is Latin America Ready to Identify Anaplastic Large Cell Lymphoma in Breast Implants Patients? Regional Encounter During the National Plastic Surgery Meeting in Cancun, Mexico. ( 29770862 )
2018
17
ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. ( 29150811 )
2018
18
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. ( 29642597 )
2018
19
Lymphomatoid Papulosis (LyP) Associated with Diffuse Large B-cell Lymphoma and Cutaneous Anaplastic Large Cell Lymphoma: LyP as a Haematological Malignancy-related Dermadrome. ( 29796688 )
2018
20
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
21
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
22
<i>ALK</i>-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation. ( 29850298 )
2018
23
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. ( 29952979 )
2018
24
A 75-Year-Old Man with Progressive Generalized Erythroderma and History of Anaplastic Large Cell Lymphoma: Answer. ( 29286975 )
2018
25
Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. ( 29494757 )
2018
26
Reply to the Editor Regarding: Magnusson MR, Deva AK Letter to the Editor 2018 May 2 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesth Plast Surg, 2018. ( 29948093 )
2018
27
Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. ( 29302687 )
2018
28
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 29800972 )
2018
29
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. ( 29390984 )
2018
30
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )
2018
31
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma. ( 29403168 )
2018
32
Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. ( 29370815 )
2018
33
Case of primary cutaneous anaplastic large cell lymphoma misdiagnosed as squamous cell carcinoma by pseudocarcinomatous hyperplasia. ( 29314194 )
2018
34
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). ( 29950528 )
2018
35
Primary Pulmonary Anaplastic Large Cell Lymphoma: A Rare Malignancy and Rare Cause of the Luftsichel Sign. ( 29854536 )
2018
36
Additional Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma-Reply. ( 29801121 )
2018
37
A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation. ( 29905579 )
2018
38
Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib. ( 29622884 )
2018
39
Reply to the Editor Regarding: Miranda RN, Clemens MW Letter to the Editor 2018 Apr 6 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesth Plast Surg, 2018. ( 29872907 )
2018
40
Anaplastic large cell lymphoma presenting as bilateral endobronchial tumor in a young boy. ( 29319039 )
2018
41
Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. ( 29945349 )
2018
42
A rare and isolated presentation of primary cutaneous anaplastic large cell lymphoma. ( 29589643 )
2018
43
Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. ( 29484689 )
2018
44
Letter to Editor: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management, APS 2018. ( 29721840 )
2018
45
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
46
Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma. ( 29744059 )
2018
47
Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema. ( 28337783 )
2017
48
A case of CD30+ ALK1- anaplastic large cell lymphoma resembling acute disseminated encephalomyelitis. ( 28427693 )
2017
49
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
50
Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience. ( 28712170 )
2017

Variations for Anaplastic Large Cell Lymphoma

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 CLU CSF1R IL9 JAK3 JUNB MCL1
2
Show member pathways
13.67 ALK CSF1R IL9 JAK3 JUNB MUC1
3
Show member pathways
13.12 ALK CSF1R IL9 JAK3 JUNB STAT3
4
Show member pathways
13.02 CSF1R IL9 JAK3 JUNB MCL1 MUC1
5 12.63 ALK CSF1R JAK3 STAT3 TFG
6
Show member pathways
12.43 IL9 JAK3 MCL1 STAT3
7
Show member pathways
11.97 JAK3 MCL1 STAT3
8 11.68 CSF1R JAK3 PTPRC STAT3
9 11.68 GZMB JAK3 JUNB PAX5 PTPRC STAT3
10
Show member pathways
11.63 JUNB MCL1 STAT3
11 11.57 GZMB IL9 PTPRC
12 11.41 JAK3 JUNB MCL1 MUC1 STAT3
13
Show member pathways
11.32 IL9 JAK3 STAT3
14
Show member pathways
11.26 CSF1R JAK3 STAT3
15 11.18 JAK3 PTPRC STAT3
16 11.18 PAX5 PTPRC STAT3 TNFRSF8
17 10.91 GZMB MCL1

GO Terms for Anaplastic Large Cell Lymphoma

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 ALK CSF1R MCL1 NPM1 STAT3
2 regulation of cell proliferation GO:0042127 9.71 ALK JAK3 JUNB TNFRSF8
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 ALK CSF1R JAK3
4 regulation of cell cycle GO:0051726 9.67 JUNB PTPRC STAT3
5 inflammatory response GO:0006954 9.65 CSF1R IL9 JAK3 STAT3 TNFRSF8
6 response to cytokine GO:0034097 9.5 JUNB MCL1 STAT3
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 JAK3 STAT3
8 interleukin-15-mediated signaling pathway GO:0035723 9.43 JAK3 STAT3
9 interleukin-21-mediated signaling pathway GO:0038114 9.37 JAK3 STAT3
10 regulation of apoptotic process GO:0042981 9.35 ALK CLU JAK3 MCL1 TNFRSF8
11 interleukin-9-mediated signaling pathway GO:0038113 9.16 IL9 JAK3
12 cytokine-mediated signaling pathway GO:0019221 9.1 CSF1R JAK3 JUNB MCL1 MUC1 STAT3

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....